The current pipeline for Hypercholesterolemia, including both homozygous and heterozygous forms of familial Hypercholesterolemia, consists of several significant products, which are being developed by leading key players, such as Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, and others.
DelveInsight’s “Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hypercholesterolemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hypercholesterolemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hypercholesterolemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hypercholesterolemia: An Overview
According to the National Institute of Health (NIH), Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from egg yolks, meat, poultry, fish, and dairy products. The body requires cholesterol to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. High levels of cholesterol increase the risk of developing heart disease.
The underlying cause of Hypercholesterolemia includes mutations in genes, such as APOB, LDLR, LDLRAP1, and PCSK9. There are several risk factors, such as lifestyle choices, including diet, exercise, and tobacco smoking, which strongly influence the amount of cholesterol in the blood. While the additional factors that impact cholesterol levels include a person’s gender, age, and health problems, like diabetes and obesity.
The cornerstone of the treatment of hypercholesterolemia is a healthy lifestyle, an optimum weight, no smoking, exercising for 150 minutes per week, and a diet low in saturated and trans-fatty acids and enriched in fiber, fruit, vegetables, and fatty fish. Plant stanols at a dose of 2 g/d can help reduce LDL-C levels. The drug class of choice is statin which can lower LDL-C from 22% to 50%. Also, they have been shown to reduce cardiovascular events in both primary and secondary prevention trials.
Hypercholesterolemia Market Key Facts
According to the National Institute of Health (NIH), more than 34 million American adults have elevated blood cholesterol levels (higher than 240 mg/dL). Inherited forms of hypercholesterolemia, which cause even higher levels of cholesterol, occur less frequently. The most common inherited form of high cholesterol is called familial hypercholesterolemia which affects about 1 in 500 people in most countries.
As per the World Health Organization, a third of ischemic heart disease is attributable to high cholesterol. Overall, raised cholesterol is estimated to cause 2.6 million deaths (4.5% of the total) and 29.7 million disability-adjusted life years (DALYS), or 2% of total DALYS.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hypercholesterolemia pipeline therapies. It also thoroughly assesses the Hypercholesterolemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Hypercholesterolemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hypercholesterolemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hypercholesterolemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hypercholesterolemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hypercholesterolemia Epidemiology, Segmented as –
Prevalent Population of Hypercholesterolemia (2019–2032)
Diagnosed Prevalent Population of Hypercholesterolemia (2019–2032)
Age-specific Diagnosed Prevalent Population of Hypercholesterolemia (2019–2032)
Type-specific Diagnosed Prevalent Population of Hypercholesterolemia [Homozygous and Heterozygous Familial Hypercholesterolemia] (2019–2032)
Treatable Cases of Hypercholesterolemia (2019–2032)
Hypercholesterolemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hypercholesterolemia market or expected to be launched during the study period. The analysis covers the Hypercholesterolemia market uptake by drugsmedicinespatient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hypercholesterolemia drugs based on their sale and market share.
The report also covers the Hypercholesterolemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hypercholesterolemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hypercholesterolemia Market Will Evolve and Grow by 2032 @
Hypercholesterolemia Therapeutics Analysis
Hypercholesterolemia is the most commonly occurring disorder that results in comorbid conditions, mainly cardiovascular disorders. High LDL cholesterol levels result in an accumulation of cholesterol-rich fatty deposits in arteries, resulting in a narrow or blocked flow of blood to vital organs, especially the heart, and brain.
The treatment paradigm of Hypercholesterolemia, which further includes subtypes, such as Homozygous and Heterozygous Familial Hypercholesterolemia, holds several options available in the market, i.e., statins, bile-acid-binding resins, cholesterol absorption inhibitors, combination cholesterol absorption inhibitor with statin and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors as well as Injectable medications. There are several FDA-approved drugs for treating Hypercholesterolemia, of which statins are the most commonly used among all, either as a monotherapy or in combination.
Hypercholesterolemia Therapeutics Assessment
The treatment paradigm of Hypercholesterolemia, which further includes subtypes, such as Homozygous and Heterozygous Familial Hypercholesterolemia holds several options available in the market, i.e., statins, bile-acid-binding resins, cholesterol absorption inhibitors, combination cholesterol absorption inhibitor with statin and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors as well as Injectable medications. There are several FDA-approved drugs for treating hypercholesterolemia of which statins are the most commonly used among all either as a monotherapy or in combination.
The current pipeline for Hypercholesterolemia, including both homozygous and heterozygous forms of familial hypercholesterolemia consists of several significant products, which are being developed by leading key players, such as Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, and others.
Hypercholesterolemia Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Hypercholesterolemia Therapies Covered in the Report Include:
Evinacumab: Regeneron Pharmaceuticals
Gemcabene: NeuroBo Pharmaceuticals
LIB003: LIB Therapeutics
Nexletol (bempedoic acid): Esperion Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hypercholesterolemia Competitive Intelligence Analysis
4. Hypercholesterolemia Market Overview at a Glance
5. Hypercholesterolemia Disease Background and Overview
6. Hypercholesterolemia Patient Journey
7. Hypercholesterolemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hypercholesterolemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypercholesterolemia Unmet Needs
10. Key Endpoints of Hypercholesterolemia Treatment
11. Hypercholesterolemia Marketed Therapies
12. Hypercholesterolemia Emerging Drugs and Latest Therapeutic Advances
13. Hypercholesterolemia Seven Major Market Analysis
14. Attribute Analysis
15. Hypercholesterolemia Market Outlook (In US, EU5, and Japan)
16. Hypercholesterolemia Companies Active in the Market
17. Hypercholesterolemia Access and Reimbursement Overview
18. KOL Views on the Hypercholesterolemia Market
19. Hypercholesterolemia Market Drivers
20. Hypercholesterolemia Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Unlock key insights and innovation in the healthcare industry with our cutting-edge market research services, paving the way for informed decisions and competitive advantage in this rapidly evolving industry @ Medical Devices Market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States